[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"morbidity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:morbidity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,68,110,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100582297","phase-2-ppis-and-in-hospital-morbidity-in-acute-variceal-bleeding-with-chronic-liver-disease-100582297",false,"NCT06861478","PPIs and In-Hospital Morbidity in Acute Variceal Bleeding With Chronic Liver Disease","In-Hospital Morbidity Associated With Proton Pump Inhibitors in Acute Variceal Bleeding and Chronic Liver Disease Treatment","Liver-IMPACT","Inclusion Criteria\n\n* Adult\n* Cirrhosis\n* Variceal Bleeding with only endoscopic findings consistent with portal hypertension complications\n* Hypovolemic shock and Variceal bleeding\n\nExclusion Criteria:\n\n* Shock of any type other than hypovolemic.\n* No cirrhotic patients\n* Patients that have severe Hepatic Encephalopathy at admission (West Haven 3 and 4)\n* Hepatorenal syndrome\n* Acute on chronic with CLIF-C \\>50 points\n* Septic patients\n* Spontaneous Bacterial Peritonitis\n\nElimination Criteria\n\n* Voluntary removal of the study\n* Violation of the study protocol\n* Patients in the no PBI group that need prolonged mecánica ventilación.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","With this study, the investigators pretend to describe intrahospital morbidity in patients living with cirrhosis (PLC) who present to the emergency department with variceal bleeding (VB).\n\nThis study is a longitudinal, prospective, experimental, analytical single-center clinical trial. The study will be performed in the Hospital Universitario \"Jose E. González\" de la Factultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.\n\nThe studied population consists of adult-age patients with previous, recent, or new diagnoses of cirrhosis who present to the ED with VH without shock, infection, or acute or chronic disease with a \\\u003C30% probability of death (CLIF-C \\\u003C50). The exclusion criteria involve minor age, Acute Liver Failure (ALF), ICU patients, Hepatorenal Syndrome, sepsis or infection, and shock on admission except for hypovolemic and CLIF-C \\>50 points. Elimination criteria involve patients who want to discontinue treatment and patients with confounding endoscopic findings (Erosive esophagitis, peptic ulcers, duodenal ulcers, bleeding GAVE, and atrophic gastritis).\n\nAfter the endoscopic intervention, the investigators will propose inclusion. After acceptance with Informed Consent, the investigators will randomize the patients to receive or not receive Omeprazole\u002F Pantoprazole 40 mg IV per day until discharge. The primary outcome will represent several morbidity situations in these patients, including Hepatic Encephalopathy grades III and IV, intra-hospital infections, re-bleeding, shock, and acute kidney failure.\n\nThe secondary outcomes include the individual analysis of each component of our compound primary outcome, mortality by day 30, differences when grouping patients by Child-Pugh stratification, and comparing results in patients receiving omeprazole for more or less than 5 days.",[27],"Morbidity",[29,27,30],"Variceal Bleeding","Proton Pump Inhibitors","RECRUITING","2026-06-10",{"date":34,"type":35},"2026-06-12","ACTUAL",{"date":37,"type":35},"2024-10-20",{"date":39,"type":21},"2026-09-20",{"name":41,"class":42},"Universidad Autonoma de Nuevo Leon","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100632033","association-between-primary-care-supply-and-population-morbidity-and-mortality-in-france-at-the-territorial-level-100632033","NCT07508423","Association Between Primary Care Supply and Population Morbidity and Mortality in France at the Territorial Level","M-OSP","Inclusion Criteria:\n\nAll individuals affiliated with any French health insurance scheme and recorded in the Système National des Données de Santé (SNDS; French National Health Data System) through the Datamart de Consommation Inter-Régimes (DCIR; French national health insurance claims database) between January 1, 2009 and December 31, 2022",true,{"count":53,"type":21},7000000,"OBSERVATIONAL","The M-OSP study investigates the association between the density of primary care professionals, including general practitioners (GPs), and population-level health outcomes across 2,850 life-health territories in France. Evidence from several OECD countries suggests higher GP density may reduce mortality, particularly cause-specific mortality such as cardiovascular deaths, but uncertainties remain regarding generalizability and other health outcomes.\n\nThis cross-sectional epidemiological study uses aggregated, territory-level data from 2009-2022, including: mortality rates (age- and sex-standardized), hospitalizations (MCO), emergency department visits, and the distribution of primary care professionals and facilities (GPs, nurses, physiotherapists, dentists, midwives, gynecologists, pediatricians, psychiatrists, and community pharmacies).",[57,27],"Mortality","NOT_YET_RECRUITING","2026-03-30",{"date":61,"type":35},"2026-04-02",{"date":63,"type":21},"2026-06-01",{"date":65,"type":21},"2027-12-31",{"name":67,"class":42},"MSPU de Pins-Justaret",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":43},"100611166","phase-2-minocycline-in-stroke-study-at-maimonides-100611166","NCT07237048","Minocycline in Stroke Study at Maimonides","Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial","\\* Inclusion criteria\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age \\>\u002F=18\n2. NIHSS 5-20 \\*National Institutes of Health Stroke Scale\\*\n3. Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO \\*(World Health Organization) \\* guidelines or acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed\n4. The onset of neurological symptoms less than 24 hours\n\n   * Exclusion criteria\n\nAn individual who meets any of the following criteria is excluded from participation in this study:\n\n1. Clinically stroke is not suspected\n2. Allergic to the Tetracycline group of medications or Intolerance to Minocycline\n3. Pregnancy or suspected pregnancy or breastfeeding\n4. Previous history of intolerance to Minocycline\n5. Acute or chronic renal failure (stage III with GFR \\*(Glomerular Filtration Rate) \\* or Creatinine threshold)\n6. Any patients with contraindications to undergo CT (Computed Tomography) \u002F MRI (Magnetic Resonance Imaging)\n7. Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission\n8. Pre-existing infectious disease requiring antibiotics\n9. Inability to tolerate enteral medications\u002Ffeeds\n10. Patient\u002F family refusal",{"count":76,"type":21},1164,[24,78],"PHASE3","The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older.\n\nThe main questions it aims to answer are:\n\n1. Does Minocycline improve \\*National Institutes of Health Stroke Scale\\* (NIHSS) scores at hospital discharge and 90 days post-stroke?\n2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\\*Modified Rankin Scale\\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care?\n\nResearchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality.\n\nParticipants will:\n\n1. Be randomly assigned by block to receive either:\n\n   Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only\n2. Undergo neurological assessments using NIHSS \\*National Institutes of Health Stroke Scale\\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke\n3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses\n\nNIHSS: \\*National Institutes of Health Stroke Scale\\*, which is stroke severity scale,\n\nmRS: \\*Modified Rankin Scale\\*, which is stroke disability scale",[81,82,83,57,27,84,85],"Stroke","Ischemia Stroke","Hemorrhagic Strokes","Cerebrovascular Accident (Stroke)","Intracerebral Haemorrhage (ICH)",[87,88,89,90,91,92,93,94,95,96,27,57,97,98,99,100],"Minocycline","Acute Stroke","Neuroprotection","Ischemic Stroke","Hemorrhagic Stroke","NIH Stroke Scale","Modified Rankin Scale (mRS)","Stroke Recovery","Stroke Treatment","Stroke Outcomes","Intravenous Thrombolysis","Mechanical Thrombectomy","Hemorrhagic Transformation","Oral antibiotic","2026-03-18",{"date":103,"type":35},"2026-03-19",{"date":105,"type":35},"2026-02-02",{"date":107,"type":21},"2028-12",{"name":109,"class":42},"Joyce Chen",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":120,"conditions":121,"keywords":128,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":43},"100572802","national-emergency-bariatric-surgery-audit-100572802","NCT06738004","National Emergency Bariatric Surgery Audit","A National Multi-centre Prospective Audit of Unplanned Surgical and Endoscopic Interventions in Patients Who Have Undergone Bariatric Surgery in the UK or Abroad","NEBSA","Inclusion Criteria:\n\n* Admissions from i) the emergency department, clinic, urgent care or primary care to the bariatric surgical team as an emergency; ii) from an inpatient team as an urgent referral; iii) a return to theatre following an elective bariatric procedure; iv) another hospital via patient transfer to a specialised unit.\n* Participants undergoing any intervention or procedure to treat or diagnose bariatric complications, (e.g., OGDs, interventional radiology, surgery, supplemental enteral or parenteral nutrition).\n\nExclusion Criteria:\n\n* age \\\u003C18 years old\n* have a length of stay \\\u003C24 hrs.\n* initial diagnosis of BSE is changed or if their readmission is found to be unrelated to previous bariatric surgery.",{"count":119,"type":21},500,"The goal of this observational study is to investigate the incidence, management, and outcomes of complications following bariatric surgery in patients in the United Kingdom. The main questions it aims to answer are:\n\n* What is the prevalence of unplanned interventions due to complications following bariatric surgery in the UK?\n* What are the current practices for managing these complications, and how do they impact patient outcomes?\n\nParticipants will:\n\nBe identified from hospitals treating patients presenting with complications following bariatric surgery.\n\nHave their data collected regarding demographics, surgical history, complications, treatments, and outcomes.\n\nResearchers will compare different management strategies and their impact on patient outcomes, with the aim of identifying best practices to improve emergency bariatric care and factors leading to patients attending as an emergency.",[122,123,124,125,126,127,27,57],"Bariatric Surgery","Postoperative Complications","Emergencies","Surgical Procedures, Operative","Outcome Assessment (Health Care)","Quality Improvement",[129,130,131,132,133,134,135,136,137,138],"Bariatric surgery","Emergency complications","National audit","Surgical outcomes","Management strategies","United Kingdom","Patient safety","Quality improvement","Morbidity and mortality","Postoperative complications","2024-12-12",{"date":141,"type":35},"2024-12-17",{"date":143,"type":35},"2023-11-09",{"date":145,"type":21},"2025-12-09",{"name":147,"class":42},"Bedfordshire Hospitals NHS Foundation Trust",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":159,"conditions":160,"keywords":165,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100473647","role-of-empathy-in-curative-treatment-outcomes-of-non-metastatic-colorectal-cancer-100473647","NCT05447611","Role of Empathy in Curative Treatment Outcomes of Non-metastatic Colorectal Cancer.","Role of Empathy in the Outcome of Curative Treatment of Non-metastatic Colorectal Cancer. Prospective Multicenter Longitudinal Study in Two Departments Covered by the Calvados Cancer Registry.","EMPACOL","Inclusion Criteria:\n\nPatients aged 18 to 75 years, French-speaking, affiliated to a social security system, having received informed information and not having expressed an unfavorable opinion to participate; carriers of non-metastatic and uncomplicated CRC (without occlusion\u002F perforation\u002Fbleeding), requiring elective therapeutic management. The included patients have a cognitive state capable of understanding and completing the questionnaires (autonomous completion).\n\nExclusion Criteria:\n\nPatients who were minors or older than 80 years, residing in a department outside Calvados or Manche, presenting a CRC other than adenocarcinoma and all metastatic forms or requiring emergency surgery (perforation, hemorrhage, occlusion), exclusive endoscopic treatment, or a missed-CRC discovered after surgery for non-oncological indications.\n\nPatients with another neoplastic disease under treatment and\u002For evolving, patients with a history of inflammatory bowel disease (Crohn's disease, ulcerative colitis) and\u002For hereditary disease predisposing to CRC (Lynch syndrome, familial polyposis) or with severe cognitive impairment preventing proper comprehension of the questionnaires. Pregnant women will be excluded.","80 Years",{"count":158,"type":21},250,"The aim of project EMPACOL will be to investigate, while taking into consideration the clinical factors known and well described in the literature, among the non-clinical factors, in particular, patient-healthcare personnel (HCP) relationship, a link between HCP's empathy perceived by the patient, and the results of the curative treatment of non-metastatic colorectal cancer, throughout the patient's care.",[161,162,27,163,164],"Non-metastatic Colorectal Cancer","Empathy","Morality","Quality of Life",[166,167,168],"colorectal cancer","empathy","outcomes","2022-07-06",{"date":171,"type":35},"2022-07-07",{"date":173,"type":21},"2022-09",{"date":175,"type":21},"2029-09",{"name":177,"class":42},"University Hospital, Caen"]